Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toca 511 and Toca FC in Recurrent Glioblastoma or Anaplastic Astrocytoma
NCT02414165Phase 3Terminated
- Sponsor
- Tocagen
- Start
- Nov 2015
- Primary completion
- May 2019
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 4
01
Overview
A Phase 3 trial of vocimagene amiretrorepvec in glioblastoma (GBM), anaplastic astrocytoma (AA), sponsored by Tocagen. Started Nov 2015; status: terminated.
02
Drugs
vocimagene amiretrorepvec
03
Conditions
glioblastoma (GBM)anaplastic astrocytoma (AA)
Beyond the preview
Go deeper on NCT02414165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02414165.